Adrenal News

Mayo Clinic and Cleveland Clinic garnered top honors among hospitals for diabetes and endocrinology-related care, as announced today in U.S. News & World Report’s Best Hospitals.

CHICAGO — Smartphone-based immunochromatographic technology can detect adrenal insufficiency and hypercortisolism and monitor physiologic variations in cortisol concentration, according to research presented at the joint meeting of the International Congress of Endocrinology and the Endocrine Society.

CHICAGO — Through a pulsed subcutaneous regimen, physiological circadian and ultradian cortisol were successfully replaced, according to research presented at the joint meeting of the International Congress of Endocrinology and the Endocrine Society.

CHICAGO — Patients with Cushing’s disease with high levels of late-night salivary cortisol could improve their condition with prompt intervention, according to research presented at the joint meeting of the International Congress of Endocrinology and the Endocrine Society.

CHICAGO — A modified-release hydrocortisone formulation could improve biochemical control for patients with congenital adrenal hyperplasia, according to research presented at the joint meeting of the International Congress of Endocrinology and the Endocrine Society.

The Endocrine Society published clinical practice guidelines to aid in earlier detection of pheochromocytomas and paragangliomas, two kinds of rare adrenal tumors that increase cardiovascular symptoms and risk for cardiovascular disease and death.

LAS VEGAS — When transitioning pediatric patients with congenital adrenal hyperplasia to adult care, physicians should treat the process as a long-term commitment rather than a singular event, according to a presenter at the AACE 23rd Annual Scientific & Clinical Congress.

The SRY test appears to be a reliable means of avoiding unnecessary prenatal dexamethasone in males, but improvements in its execution are needed, according to recent findings.

An inherited mutation in the ARMC5 gene is a frequent cause of primary macronodular adrenal hyperplasia, a rare cause of Cushing’s syndrome.

A Phase II trial evaluating a second generation antisense drug designed to block growth hormone receptor expression, and thereby reduce levels of the hormone insulin-like growth factor-1 in the blood, has achieved positive results as a potential treatment for diseases including acromegaly.